Search

A 76-year-old woman with AL amyloidosis and multiple myeloma experienced various toxicities and lack of efficacy with different drug treatments. She developed symptoms such as fever, chills, hair loss, neurologic spells, fatigue, and neuropathy during treatment with daratumumab and carfilzomib. Despite trying multiple medications, including bortezomib, dexamethasone, selinexor, and prednisone, the woman faced challenges with efficacy and side effects. Ultimately, she found success with teclistamab after experiencing a range of responses and adverse reactions to different treatments. [Extracted from the article]

A 69-year-old man with IgG kappa multiple myeloma experienced a lack of efficacy with daratumumab, pomalidomide, and dexamethasone treatment, leading to disease progression. He also developed pharyngeal discomfort and dysphonia while receiving pentamidine. Despite treatment with tranexamic-acid for laryngeal oedema, he did not show improvement, eventually requiring a tracheostomy. However, at his two-month follow-up, he reported being asymptomatic with improved voice and stable respiratory function. [Extracted from the article]

The article from Reactions Weekly discusses two case reports of elderly patients with chronic lymphocytic leukaemia (CLL) who exhibited lack of efficacy during treatment with various drugs. In the first case, a woman with CLL did not respond to daratumumab and eventually died due to disease progression. In the second case, a patient with CLL and breast cancer experienced worsening clinical condition despite treatment with multiple drugs, leading to death from disease progression. [Extracted from the article]

A 16-year-old girl with anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis showed a lack of efficacy when treated with rituximab, immune globulin, and steroids. Despite receiving IV immune globulin, steroids, plasma exchange, and rituximab, she continued to experience hallucinations, aggression, and seizures. However, after switching to daratumumab, there was a significant improvement in her behavioral and psychiatric symptoms. [Extracted from the article]

A 44-year-old woman developed daratumumab-associated leukoencephalopathy while being treated for multiple myeloma with daratumumab, bortezomib, and methylprednisolone. She presented with symptoms such as facial weakness, numbness, slurred speech, and memory deficits, which resolved initially but worsened later. Neuroimaging and cerebrospinal fluid analysis supported the diagnosis of daratumumab-associated leukoencephalopathy. Treatment with methylprednisolone and immune-globulin led to improvement, and the patient remained symptom-free after stopping daratumumab and bortezomib. [Extracted from the article]

A 74-year-old woman experienced worsening ischaemic retinopathy, optic neuropathy, neovascular glaucoma, and bilateral vitreous hemorrhages while being treated with daratumumab for heavy chain deposition disease. Despite being diagnosed with HCDD and receiving daratumumab and immune-globulin therapy, her condition deteriorated, leading to profound vision loss. The woman's treatment with daratumumab was discontinued, and she ultimately required surgical intervention as her condition progressed. [Extracted from the article]

In a phase 2 study, three patients with multiple myeloma developed adverse reactions during treatment with daratumumab, carfilzomib, lenalidomide, and dexamethasone. Patient 1 experienced carfilzomib-related thrombotic microangiopathy, leading to discontinuation of carfilzomib. Patient 2 developed grade 3 atrial fibrillation, and Patient 3 developed treatment-related heart failure. These cases highlight potential risks associated with these medications in the treatment of multiple myeloma. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventIn a study of 28 paediatric patients, et al. paediatric patients [sexes and exact ages not stated] were described, who developed itching and rash (one patient) and anaphylaxis (one patient) during first dose of IV daratumumab 16 mg/kg weekly [indications, durations of treatments to reactions onsets and outcomes not stated]. [Extracted from the article]

In a retrospective study of 53 patients who received daratumumab for newly diagnosed multiple myeloma, two patients developed cytomegalovirus (CMV) infection. One patient experienced pneumonia and the other had CMV retinitis. The patient with CMV retinitis received antiviral therapy with ganciclovir and foscarnet. The study does not provide information on the ages or sexes of the patients, as well as the specific details of their treatments or outcomes. [Extracted from the article]

In a retrospective study involving 80 patients, a case was described where an adult patient with multiple myeloma exhibited lack of efficacy during treatment with bortezomib, daratumumab, dexamethasone, and thalidomide. The patient received a combination of these drugs, but after two cycles of treatment, disease progression was observed. This case highlights the need for further research and alternative treatment options for patients with multiple myeloma. [Extracted from the article]

This article from Reactions Weekly presents three case reports of patients with renal impairment who experienced serious complications while receiving treatment with daratumumab and/or dexamethasone for multiple myeloma. In the first case, a patient developed a serious infection secondary to daratumumab and died. In the second case, a patient discontinued daratumumab due to severe pneumonia and ultimately died due to the progression of the primary disease. The third case involved a 54-year-old man with stage IV renal impairment who had a progression of the disease and died. These case reports highlight potential risks and complications associated with this treatment regimen. [Extracted from the article]

In a retrospective study of 374 patients with POEMS syndrome, five patients were identified who did not respond to various drug treatments. Case 1 involved a patient who did not respond to daratumumab and dexamethasone but later achieved stability with carfilzomib, pomalidomide, and dexamethasone. Case 2 described a patient who did not respond to multiple treatment regimens and eventually passed away. Case 3 involved a patient who did not respond to daratumumab, pomalidomide, bortezomib, and dexamethasone. Case 4 described a patient who did not respond to carfilzomib, lenalidomide, and dexamethasone but achieved a complete response with daratumumab, pomalidomide, and dexamethasone. Case 5 involved a patient who did not respond to pomalidomide and dexamethasone but achieved a complete response with carfilzomib and dexamethasone. [Extracted from the article]

A retrospective study involving 74 patients treated between 2017 and 2021 reported a case of lack of efficacy of daratumumab in a patient with multiple myeloma. Despite receiving treatment with daratumumab, the patient experienced progression of the disease, ultimately leading to their death. The study highlights the importance of monitoring treatment efficacy in patients with multiple myeloma. [Extracted from the article]

In a study of 8 patients with relapsed/refractory multiple myeloma, three patients exhibited a lack of efficacy during treatment with selinexor, daratumumab, and dexamethasone. The patients, aged between 44-78 years, had previously received treatment with lenalidomide. Despite receiving the combination treatment, their disease progressed, indicating a lack of effectiveness. This information is based on a single-arm, prospective, non-interventional, real-world study conducted between February and May 2023. [Extracted from the article]

A case report published in Reactions Weekly describes a patient with myeloma and renal insufficiency who exhibited lack of efficacy during treatment with daratumumab, bortezomib, dexamethasone, and lenalidomide. The patient received IV daratumumab, SC bortezomib, dexamethasone, and lenalidomide, but experienced rapid disease progression and eventually died. The specific cause of death was not stated. This case highlights the need for further research and alternative treatment options for patients with myeloma and renal insufficiency. [Extracted from the article]

In a single-center retrospective study, a patient with multiple myeloma (MM) developed interstitial pneumonia and cytomegalovirus (CMV) reactivation during treatment with daratumumab and bortezomib. The patient received additional treatments including thalidomide and dexamethasone. The CMV reactivation and interstitial pneumonia were successfully treated with ganciclovir and valganciclovir. This case highlights the potential side effects of daratumumab and bortezomib in MM patients. [Extracted from the article]

In a case series involving two patients, a 14-year-old boy and a 9-year-old boy, both exhibited lack of efficacy during their respective cancer treatments. The first patient, who had a history of kidney transplant, initially received rituximab monotherapy for a large B-cell neoplasm but experienced disease progression. He then underwent chemoimmunotherapy with bortezomib, cyclophosphamide, dexamethasone, and daratumumab, but relapsed while on therapy. After further examination, he was diagnosed with posttransplant plasmablastic lymphoma and received EPOCH chemotherapy, achieving remission. The second patient, who had a history of heart transplant, underwent surgery for intestinal obstruction and was subsequently diagnosed with posttransplant plasmablastic lymphoma. He received EPOCH chemotherapy with bortezomib but unfortunately died due to lack of efficacy. [Extracted from the article]

A 63-year-old woman with IgD multiple myeloma experienced various toxicities during her treatment with antineoplastic drugs. She developed a rash and neuropathy while receiving bortezomib, neurological side effects with dexamethasone, and pancytopenia, polyneuropathy, worsening GERD, and drug intolerance with cyclophosphamide, bortezomib, daratumumab, and dexamethasone. She required transfusion and hospitalization due to pancytopenia but eventually showed improvement in her condition. [Extracted from the article]

A retrospective study involving 20 patients diagnosed with multiple myeloma found that an elderly patient exhibited a lack of efficacy during treatment with daratumumab. The patient had progressive disease despite receiving daratumumab, indicating that the treatment was not effective. [Extracted from the article]

A retrospective study was conducted on 19 patients with multiple myeloma who were treated with daratumumab. Two patients in the study showed a lack of efficacy, as they experienced disease progression despite receiving daratumumab. The study suggests that daratumumab may not be effective in treating multiple myeloma in these cases. The age and sex of the patients were not provided in the study. [Extracted from the article]

A 66-year-old man with immunoglobulin-G kappa (κ) multiple myeloma experienced a lack of efficacy during treatment with cyclophosphamide, daratumumab, and dexamethasone. Despite undergoing autologous stem cell transplant and receiving multiple lines of therapy, the patient's disease progressed. This suggests that the combination of cyclophosphamide, daratumumab, and dexamethasone was not effective for his condition. The patient later underwent a bone marrow biopsy, which revealed Snapper-Schneid bodies. [Extracted from the article]

A 39-year-old man with IgA multiple myeloma exhibited lack of efficacy during treatment with carfilzomib, daratumumab, and dexamethasone. Despite receiving four cycles of this combination protocol, his myeloma became refractory and he developed cutaneous nodules. A positron emission tomography scan confirmed disease progression with cutaneous infiltration, pathological retroperitoneal lymph nodes, and multiple new bony lesions. [Extracted from the article]

A retrospective study involving 40 patients with newly diagnosed multiple myeloma found that a patient exhibited lack of efficacy during treatment with daratumumab, bortezomib, thalidomide, and dexamethasone. The patient had high-risk features and received induction therapy followed by autologous stem-cell transplantation. However, at the last disease assessment, the patient showed disease progression, indicating that the treatment was not effective. [Extracted from the article]

In a retrospective study of 14 patients, three individuals (2 men and 1 woman) between the ages of 45 and 58 experienced adverse reactions while being treated with daratumumab for pure red cell aplasia (PRCA). Two patients developed progressive multifocal leukoencephalopathy (PML) or an infusion reaction, while the third patient did not respond to the treatment. The patients had previously undergone stem cell transplantation and had received various medications. Unfortunately, one patient died as a result of PML. [Extracted from the article]

A man in his late 40s experienced a lack of efficacy after receiving treatment with daratumumab and rituximab for type I cryoglobulinaemia (TIC) secondary to monoclonal gammopathy of undetermined significance (MGUS). The man had a medical history of hypertension, type 2 diabetes mellitus, heart failure, and a chronic ulcer. Despite multiple hospitalizations and treatments, including plasma exchange therapy and amputations, the disease continued to progress. The man eventually stabilized and did not experience further disease progression. [Extracted from the article]

This article discusses two case reports of patients who experienced lack of efficacy during treatment with rituximab and daratumumab for pure red cell aplasia (PRCA). The first patient, a 52-year-old man with high-risk acute myeloid leukemia, received a stem cell transplant and subsequently started receiving rituximab and daratumumab but remained transfusion dependent. After undergoing therapeutic plasma exchange, he became transfusion independent but developed transfusion-associated iron overload. The second patient, a 21-year-old man with severe aplastic anemia and paroxysmal nocturnal hemoglobinuria, also received rituximab and daratumumab but remained transfusion dependent. After therapeutic plasma exchange, he developed transfusion-associated iron overload and started chelation therapy. [Extracted from the article]

A 76-year-old man with IgA/Kappa multiple myeloma exhibited lack of efficacy during treatment with daratumumab, lenalidomide, and bortezomib. Despite undergoing multiple lines of therapy, the multiple myeloma remained refractory. The patient then received Lu-177-PSMA-I&T, which was well tolerated with slight clinical improvement. However, he experienced a femoral fracture and subsequently died. The cause of death was not stated. [Extracted from the article]

A 76-year-old man with IgA/Kappa multiple myeloma exhibited lack of efficacy during treatment with daratumumab, lenalidomide, and bortezomib. Despite undergoing multiple lines of therapy, the multiple myeloma remained refractory. The patient then received Lu-177-PSMA-I&T, which was well tolerated with slight clinical improvement. However, he experienced a femoral fracture and subsequently died. [Extracted from the article]

This article discusses the toxicities experienced by five patients undergoing treatment for multiple myeloma with the drugs pomalidomide, daratumumab, and lenalidomide. The patients experienced various side effects, including injection-site reactions, chronic fatigue, mental fog, peripheral neuropathy, and skin rash. The article provides detailed case studies of two patients, a 58-year-old woman and a 58-year-old man, describing their treatment history and the specific toxicities they experienced. The patients' symptoms improved with changes in their treatment regimens. [Extracted from the article]

In a retrospective study, a patient with relapsed or refractory multiple myeloma developed neutropenia while receiving treatment with daratumumab, pomalidomide, and dexamethasone. The patient's age, sex, dosages, and duration of treatment were not provided. The adverse drug reaction led to the tapering of pomalidomide. [Extracted from the article]

A case series published in Reactions Weekly describes a 9-year-old girl with various medical conditions who developed transient neutropenia while receiving daratumumab treatment before a heart-kidney transplant. The girl had DiGeorge syndrome, repaired tetralogy of fallot/patent ductus arteriosus, end-stage renal disease requiring dialysis, heart failure, severe epistaxis, and thrombocytopenia related to Evans syndrome. After receiving rituximab and IV immune-globulin with therapeutic plasma exchange, she started daratumumab infusions but experienced transient neutropenia as a side effect. [Extracted from the article]

In a retrospective cohort study, a patient with immunoglobulin light chain amyloidosis was treated with daratumumab and dexamethasone. However, the patient did not show any response to the treatment and was classified as a non-responder. The study did not provide specific information about the patient's age, sex, dosages, or routes of administration. This suggests that daratumumab and dexamethasone may not be effective for all patients with this condition. [Extracted from the article]

In a retrospective study, two men aged 65 and 69 years were found to have a lack of efficacy during treatment with daratumumab, rituximab, or erythropoietin for pure red cell aplasia (PRCA). Both patients had myelodysplastic neoplasm and underwent allogenic hematopoietic stem cell transplant. Despite receiving rituximab and erythropoietin, their isohemagglutinin levels remained elevated, indicating a lack of efficacy. One patient received daratumumab and experienced resolution of PRCA, while the other patient received erythrocyte transfusions. [Extracted from the article]

This article discusses a retrospective review study of eight patients who experienced various toxicities while being treated with bortezomib or daratumumab for warm autoimmune hemolytic anemias (WAIHA) or cold agglutinin disease (CAD). The study included three men and one woman, aged between 69-78 years. Three patients developed pain at the site of injection, fever, dizziness, or atrial fibrillation during treatment, while one patient did not respond to the treatment. The article provides specific cases of patients who experienced these toxicities, including their age, diagnosis, and outcomes. [Extracted from the article]

A 70-year-old man with plasma cell leukemia experienced a lack of efficacy while receiving daratumumab treatment. The man had previously been diagnosed with multiple myeloma and had undergone chemotherapy. In July 2023, he developed weakness and raccoon eyes, leading to a diagnosis of secondary PCL. Despite receiving daratumumab combination therapy, his condition worsened and he passed away two days after admission. [Extracted from the article]

A female patient with a history of morbid obesity and myeloma experienced an infusion-related reaction while receiving daratumumab treatment for disease relapse. The reaction, which included shortness of breath and hypoxemia, was diagnosed as a grade 3 infusion-related reaction secondary to daratumumab. The patient's daratumumab therapy was discontinued, and she was treated with premedication, oxygen, steroids, beta-2 agonists, and diphenhydramine. After treatment, she recovered from the reaction and was able to tolerate a split dose of daratumumab. [Extracted from the article]

A 41-year-old woman with alcoholic cirrhosis underwent an ABO incompatible liver transplant and developed acute antibody mediated rejection. She was treated with daratumumab, eculizumab, and steroids, but the treatment was unsuccessful, and she continued to have de novo donor specific antibodies. As a result, she received off-label imlifidase followed by therapy with immune globulin and rituximab, which successfully resolved the rejection. This case highlights the challenges and potential solutions in treating antibody mediated rejection after liver transplantation. [Extracted from the article]

An 83-year-old woman with acquired haemophilia A (AHA) experienced a lack of efficacy during treatment with prednisolone and rituximab. Despite receiving these medications, the inhibitor titer increased, indicating that the treatment was not effective. Due to her multiple health conditions, she was unable to receive intensive outpatient immunosuppressive therapy and instead received off-label daratumumab. After 16 weeks of daratumumab treatment, the inhibitor titer decreased without any observed adverse reactions or infections. [Extracted from the article]

In a non-interventional study involving 23 patients, a case was reported of a patient with multiple myeloma and renal insufficiency who developed acute pancreatitis while being treated with daratumumab, bortezomib, thalidomide, and dexamethasone. The patient received various doses of these medications over several cycles. Acute pancreatitis was identified as the main adverse event related to the treatment, leading to the discontinuation of the medications. The study provides insight into the potential risks associated with these drugs in patients with multiple myeloma and renal insufficiency. [Extracted from the article]

A case study published in Reactions Weekly describes a man with cardiac amyloidosis who experienced lack of efficacy with bortezomib and lenalidomide treatments. The patient was then started on daratumumab and listed for heart transplantation. However, the flow cytometry crossmatch (FCMXM) test showed false-positive results due to interference from daratumumab, delaying the transplantation matching process. Eventually, the patient received a matched deceased donor transplant without complications. This case highlights the potential for interference with laboratory tests when using certain medications. [Extracted from the article]

A 60-year-old man with stage IV plasmablastic lymphoma (PBL) exhibited lack of efficacy during treatment with gemcitabine, oxaliplatin, and daratumumab. He had a history of chronic kidney disease, coronary artery disease, chronic back pain, and peripheral arterial disease. After initial treatment with methotrexate and the DA-EPOCH regimen, he achieved a complete response but later relapsed. Despite 8 cycles of treatment, his PBL progressed. He was then started on teclistamab and developed viral pneumonia, which was successfully treated. He achieved a complete response and remained on teclistamab therapy. [Extracted from the article]

A retrospective study examined the efficacy of daratumumab, a treatment for multiple myeloma, in 508 patients with newly diagnosed multiple myeloma. The study included a patient who underwent autologous stem cell transplant and received daratumumab as induction therapy. However, three months later, the patient died due to disease progression, indicating a lack of efficacy. This information suggests that daratumumab may not be effective in treating multiple myeloma in some cases. [Extracted from the article]

In a study involving 110 patients, three patients developed adverse reactions while receiving daratumumab for multiple myeloma. The reactions included an allergic reaction, cystitis, and deep vein thrombosis. The patients received subcutaneous daratumumab and the therapy was discontinued permanently for the patient with the allergic reaction. The duration of treatment, outcomes, and therapy status for the other two patients were not provided. [Extracted from the article]

A 51-year-old man experienced severe adverse reactions while being treated with daratumumab for multiple myeloma. The reactions included bronchospasm, flushing, chest pain, and general itching. The patient's vital signs were also affected, with low oxygen saturation, high blood pressure, and an elevated heart rate. After conducting an allergy study, a desensitization protocol was carried out successfully, allowing the patient to continue receiving daratumumab treatment under a modified protocol. [Extracted from the article]

A 35-year-old woman with multiple myeloma (MM) relapse exhibited lack of efficacy during treatment with daratumumab, lenalidomide, and dexamethasone. She had previously undergone chemotherapy and autologous stem cell transplantation. However, in the fifteenth week of treatment, she experienced pain in her left shoulder and subsequent imaging revealed disease progression. This case highlights the lack of efficacy of the daratumumab, lenalidomide, and dexamethasone regimen in this particular patient, leading to her referral to a clinical study. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventIn a pre-post interventional quality improvement study involving 102·patients with relapsed/refractory multiple myeloma, 2·patients [ages and sexes not stated] were described, who developed infusion-related reactions after the first dose of SC daratumumab [dosages, outcomes and exact times to reaction onsets not stated].The patients had been receiving dexamethasone and hyaluronidase, concomitantly. [Extracted from the article]

An 83-year-old woman experienced multiple adverse effects and lack of efficacy while undergoing treatment for multiple myeloma and deep venous thrombosis prophylaxis. The adverse effects included diarrhoea, pancytopenia, and DNMT3A-positive pure red cell aplasia (PRCA). The treatments she received included daratumumab, dexamethasone, lenalidomide, daratumumab/hyaluronidase, aspirin, and epoetin alfa. The specific dosages and durations of the treatments were not provided in the article. [Extracted from the article]

A 57-year-old woman with proliferative glomerulonephritis with monoclonal immunoglobulin deposition (PGNMID) experienced lack of efficacy with rituximab and unspecified steroids. She was then treated with daratumumab, which resulted in transient nausea, vomiting, back pain, and constipation. Despite these side effects, her kidney function improved after completing the daratumumab treatment. This case report highlights the potential toxicities associated with daratumumab and the need for further research in this area. [Extracted from the article]

An 83-year-old man developed progressive-multifocal-leukoencephalopathy while being treated for multiple myeloma with daratumumab, bortezomib, and dexamethasone. He also experienced lack of efficacy when treated with mefloquine and mirtazapine for progressive multifocal leukoencephalopathy. The man presented with right hemiparalysis and visual disturbance, and tests revealed high intensity signals in his brain. Despite discontinuing the initial treatment and starting a new one, his condition did not improve, and he passed away six months after symptoms onset. [Extracted from the article]